To date, small in vivo series have been reported using the presumptive tau PET ligand flortaucipir (FTP) in patients with clinical diagnoses of progressive supranuclear palsy, Microtubule-associated protein tau (MAPT)-related FTLD and corticobasal syndrome,11–13 suggesting that tracer uptake is present in areas of expected neurodegeneration. The gene discussed is MAPT; the disease is Classical progressive supranuclear palsy.